<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935320</url>
  </required_header>
  <id_info>
    <org_study_id>HTL0016878-102</org_study_id>
    <secondary_id>18-018</secondary_id>
    <secondary_id>2018-003685-14</secondary_id>
    <nct_id>NCT04935320</nct_id>
  </id_info>
  <brief_title>Comparison of Blood Levels of HTL0016878 From an Oral Capsule and an Oral Solution</brief_title>
  <official_title>Phase 1, Randomised, Open-label, 3-period Crossover, Single Dose Study in Healthy Subjects, to Assess Relative Bioavailability From an Oral Capsule of HTL0016878 Citrate Salt Versus an Oral Solution of HTL0016878 Hydrochloride Salt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heptares Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heptares Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, open-label, 3-period, crossover single dose study to assess the&#xD;
      relative bioavailability of two formulations of HTL0016878: an oral solution of HCl salt form&#xD;
      (the reference product) and an oral capsule containing citrate salt (the test product); and&#xD;
      of the effect of food on the pharmacokinetics of the capsule formulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifteen healthy male or female subjects will be enrolled. Each subject will have 3 study&#xD;
      sessions and receive a single oral dose of 10 mg HTL0016878 on Day 1 of each study session.&#xD;
      Subjects will receive the HTL0016878.HCl oral solution in the fasted state in 1 session, and&#xD;
      the HTL0016878.citrate capsule, in the fasted state and after a high-fat meal, respectively,&#xD;
      in the other 2 sessions. Each subject will be randomised to 1 of 3 treatment sequences (5&#xD;
      subjects to each sequence). There will be a washout of at least 10 days between doses.&#xD;
      Subjects will be screened within 35 days before their first dose of HTL0016878. In each study&#xD;
      session, subjects will be resident on the ward from the day before dosing (Day -1) until&#xD;
      completion of procedures 72 h after their dose (Day 4). Subjects will return for a follow up&#xD;
      visit 10-13 days after their final dose of trial medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Actual">October 29, 2021</completion_date>
  <primary_completion_date type="Actual">October 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of HTL0016878 in plasma Cmax</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of HTL0016878 in plasma AUC</measure>
    <time_frame>0-72 hours</time_frame>
    <description>Pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>Baseline up to 13 days post-dose</time_frame>
    <description>Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Oral Solution Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTL0016878.HCl 10 mg, single dose, oral solution, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Capsule Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTL0016878.citrate 10 mg, single dose, oral capsule, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Capsule Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HTL0016878.citrate 10 mg, single dose, oral capsule, fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0016878.HCl Solution 10 mg</intervention_name>
    <description>Oral solution fasted</description>
    <arm_group_label>Oral Solution Fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTL0016878.Citrate Capsule 10 mg</intervention_name>
    <description>Oral capsule fed or fasted</description>
    <arm_group_label>Oral Capsule Fasted</arm_group_label>
    <arm_group_label>Oral Capsule Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or females, aged 18-50 years&#xD;
&#xD;
          2. Female subjects must agree to use highly effective contraception&#xD;
&#xD;
          3. Weigh 60 kg or more, with a BMI in the range 18.0-30.0 kg/m2&#xD;
&#xD;
          4. Sufficient intelligence to understand the nature of the trial&#xD;
&#xD;
          5. Willingness to give written consent to participate&#xD;
&#xD;
          6. Agree to use the contraception requirements of the trial&#xD;
&#xD;
          7. Agree not to donate blood or blood products during the study and for up to 3 months&#xD;
             after the administration of the trial medication&#xD;
&#xD;
          8. Willingness to give written consent to have data entered into The Overvolunteering&#xD;
             Prevention System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Woman who is pregnant or lactating&#xD;
&#xD;
          2. Clinically relevant abnormal history, physical findings, ECG, or laboratory values&#xD;
&#xD;
          3. Presence or history of acute or chronic illness, or mental health problem&#xD;
&#xD;
          4. Impaired neurological, endocrine, thyroid, cardiovascular, respiratory,&#xD;
             gastrointestinal, hepatic or renal function, diabetes mellitus, coronary heart&#xD;
             disease, or history of any psychiatric disorder or psychotic mental illness&#xD;
&#xD;
          5. Cancer during the 5 years before screening&#xD;
&#xD;
          6. Supine blood pressure and heart rate outside the ranges: 90-140 mm Hg systolic and&#xD;
             50-90 mm Hg diastolic blood pressure; heart rate 45-80 beats/min&#xD;
&#xD;
          7. Supine QT interval (QTcF) outside the ranges 300-450 msec (men) and 300-470 msec&#xD;
             (women)&#xD;
&#xD;
          8. Personal or family history of long QT syndrome or family sudden death&#xD;
&#xD;
          9. Positive test for hepatitis B, hepatitis C or HIV&#xD;
&#xD;
         10. Aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase or&#xD;
             total bilirubin levels &gt; 1.5 times the upper limit of normal&#xD;
&#xD;
         11. Creatinine clearance &lt; 80 mL/min/1.73 m2&#xD;
&#xD;
         12. Presence or history of drug or alcohol abuse in the past 5 years; or regular intake of&#xD;
             more than 21 units of alcohol weekly (for men) or 14 units of alcohol weekly (for&#xD;
             women); or use of cigarettes, tobacco and/or nicotine-containing products during the 3&#xD;
             months before dosing&#xD;
&#xD;
         13. Evidence of drug abuse or positive alcohol or cotinine test results&#xD;
&#xD;
         14. Positive pregnancy test&#xD;
&#xD;
         15. Habitual and heavy consumption of caffeinated beverages&#xD;
&#xD;
         16. Use of a prescription or over-the-counter medicine, any herbal remedy, or nutritional&#xD;
             supplement&#xD;
&#xD;
         17. Receipt of a vaccine against COVID-19 in the 14 days before dosing&#xD;
&#xD;
         18. Received live attenuated vaccination within 6 weeks prior to Screening&#xD;
&#xD;
         19. History of severe allergies&#xD;
&#xD;
         20. Use of any drugs that are inhibitors of CYP2D6&#xD;
&#xD;
         21. Poor metaboliser of CYP2D6&#xD;
&#xD;
         22. History of epilepsy or seizures&#xD;
&#xD;
         23. Any disease associated with cognitive impairment and/or psychosis&#xD;
&#xD;
         24. Suicidal thoughts or ideation, or insomnia&#xD;
&#xD;
         25. Any history of mental illness (including anxiety, depression), which required medical&#xD;
             intervention&#xD;
&#xD;
         26. Presence or history of severe adverse reaction to any drug&#xD;
&#xD;
         27. Surgery or medical condition that might affect absorption of medicines&#xD;
&#xD;
         28. Receipt of an investigational product as part of another clinical trial within the 3&#xD;
             months before dosing in this study&#xD;
&#xD;
         29. Receipt of HTL0016878 in a previous clinical trial&#xD;
&#xD;
         30. Loss of more than 400 mL blood during the 3 months before dosing&#xD;
&#xD;
         31. Unwilling to eat a high-fat breakfast&#xD;
&#xD;
         32. Possibility that the volunteer will not cooperate with the requirements of the&#xD;
             protocol&#xD;
&#xD;
         33. Objection by GP to volunteer entering trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research Ltd (HMR)</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relative Bioavailability</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

